



## Adverum Biotechnologies to Participate in Upcoming Conferences

March 18, 2019

MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company's participation in several upcoming conferences:

Event: Chardan's In Vivo Gene Therapy and Gene Editing Summit  
Panel Title: Gene Therapy and Gene Editing to the Retina  
Panel Participant: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum Biotechnologies  
Date: Monday, March 18, 2019  
Time: 5:05 – 6:05 pm ET  
Location: Miami, Florida

Event: Retina World Congress Unplugged  
Panel Title: Cell and Gene Therapy  
Panel Moderator: Pravin Dugel, M.D., managing partner of Retinal Consultants of Arizona and clinical professor at the Department of Ophthalmology at the Keck School of Medicine, University of Southern California  
Panel Participant: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum Biotechnologies  
Date: Thursday, March 21, 2019  
Time: 10:07 – 10:34 am ET  
Location: Fort Lauderdale, FL

Event: 2019 Cell & Gene Meeting on the Mediterranean  
Presentation by: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum Biotechnologies  
Date: April 23, 2019  
Time: 1:35 pm CET  
Location: Hotel Arts Barcelona, Marina 19-21, 08005 Barcelona, Spain  
Webcast: <http://www.meetingonthemed.com/webcast>

### **About Adverum Biotechnologies, Inc.**

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. As a leader in ophthalmic gene therapy, Adverum has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine. Adverum's core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit [www.adverum.com](http://www.adverum.com).

Investor and Media Inquiries:  
Amy Figueroa, CFA  
Investor Relations Consultant  
[afigueroa@adverum.com](mailto:afigueroa@adverum.com)  
650-823-2704

 ADVERUM\_ID\_RGB  
200x49.jpg

Source: Adverum Biotechnologies, Inc.